Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Drug Insights
4 min read
Unleashing the Power of Meprobamate: A Comprehensive Review on R&D Breakthroughs
14 September 2023
This article summarized the latest R&D progress of Meprobamate, the Mechanism of Action for Meprobamate, and the drug target R&D trends for Meprobamate.
Advanced Tech.
9 min read
Wang Shaomeng's research group reports AR receptor PROTAC drug ARD-1676, with a bioavailability as high as 99%
14 September 2023
The research group of Wang Shaomeng recently published a paper in JMC, reporting the discovery of ARD-1676 and characterizing its preclinical properties.
Drug Insights
4 min read
A Comprehensive Review of Lubiprostone's R&D Innovations and Drug Target Mechanism
14 September 2023
This article summarized the latest R&D progress of Lubiprostone, the Mechanism of Action for Lubiprostone, and the drug target R&D trends for Lubiprostone.
Latest Hotspot
3 min read
Opus Genetics reports the administration of their gene therapy OPGx-LCA5 to the first participant of their phase 1/2 clinical trial
14 September 2023
Opus Genetics has administrated to the first patient in its first-in-human Phase 1/2 clinical trial for OPGx-LCA5.
Drug Insights
4 min read
Pharmaceutical Insights: Linaclotide's R&D Progress and its Mechanism of Action on Drug Target
14 September 2023
This article summarized the latest R&D progress of Linaclotide, the Mechanism of Action for Linaclotide, and the drug target R&D trends for Linaclotide.
Drug Insights
4 min read
Exploring Leflunomide's Revolutionary R&D Successes and its Mechanism of Action on Drug Target
14 September 2023
This article summarized the latest R&D progress of Leflunomide, the Mechanism of Action for Leflunomide, and the drug target R&D trends for Leflunomide.
Latest Hotspot
3 min read
Eloxx Pharmaceuticals Shares Program Report on Phase 2 Alport Trial involving ELX-02
14 September 2023
Eloxx Pharmaceuticals, Inc. provided new information on the development of ELX-02 in the context of handling Alport syndrome caused by nonsense mutations.
Drug Insights
4 min read
Decoding Lacosamide: A Comprehensive Study of its R&D Trends and Mechanism on Drug Target
14 September 2023
This article summarized the latest R&D progress of Lacosamide, the Mechanism of Action for Lacosamide, and the drug target R&D trends for Lacosamide.
Drug Insights
4 min read
Deep Scientific Insights on Isosorbide Dinitrate's R&D Progress
14 September 2023
This article summarized the latest R&D progress of Isosorbide Dinitrate, the Mechanism of Action for Isosorbide Dinitrate, and the drug target R&D trends for Isosorbide Dinitrate.
Latest Hotspot
4 min read
Janssen presents an application for Marketing Authorisation to the EMA, requesting endorsement for Erdafitinib's utilization in the management of patients
14 September 2023
Janssen Pharmaceuticals filed a Marketing Authorisation Application with EMA to get approval for Erdafitinib. The drug is for adult patients with advanced or metastatic urothelial carcinoma, showing progression after a PD-1/PD-L1 inhibitor therapy, with susceptible FGFR3 mutations.
Drug Insights
4 min read
An In-depth Analysis of Icosapent Ethyl's R&D Progress
14 September 2023
This article summarized the latest R&D progress of Icosapent Ethyl, the Mechanism of Action for Icosapent Ethyl, and the drug target R&D trends for Icosapent Ethyl.
Valuable Targets
7 min read
Research Progress and Future of KRAS G12C Inhibitors
14 September 2023
Understanding the role of KRAS G12C is essential for developing targeted therapies that can specifically inhibit this mutation, offering potential treatment options for patients with KRAS G12C-mutated cancers.